Home › Valeant misses expectations as loses $89 million in Q4, $116M for full year
 

Keywords :   


Valeant misses expectations as loses $89 million in Q4, $116M for full year

2013-02-28 23:56:10| Biotech - Topix.net

Valeant Pharmaceuticals International missed expectations as it net loss grew in the fourth-quarter and full-year amid higher operating expenses and items related to restructuring and acquisitions.

Tags: year full million expectations

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.07Tropical Storm Beryl Public Advisory Number 35
07.07Summary for Tropical Storm Beryl (AT2/AL022024)
07.07Tata talks under way but no full jobs guarantee - Reynolds
07.07Tropical Storm Beryl Potential Storm Surge Flooding Map
07.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
07.07Tropical Storm Beryl Graphics
07.07Tropical Storm Beryl Forecast Discussion Number 35
07.07Tropical Storm Beryl Storm Surge Watch/Warning Map
More »